Positive clinical trial results are a significant milestone for biotech companies, often leading to increased investor confidence and potential partnerships or funding opportunities. For PDS Biotech, meeting the primary endpoints in the VERSATILE-002 Phase 2 trial demonstrates the efficacy and potential of their product, which could significantly impact the company's valuation and stock price in the short term.